Curis (CRIS) Resumen de Acciones
Curis, Inc, empresa de biotecnología, se dedica al descubrimiento y desarrollo de fármacos candidatos para el tratamiento de cánceres humanos en Estados Unidos. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 2/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
CRIS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Curis, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$1.80 |
| Máximo en las últimas 52 semanas | US$39.00 |
| Mínimo de 52 semanas | US$1.54 |
| Beta | 3.09 |
| Cambio en 1 mes | -61.94% |
| Variación en 3 meses | -81.64% |
| Cambio de 1 año | -95.08% |
| Variación en 3 años | -99.27% |
| Variación en 5 años | -99.90% |
| Variación desde la OPV | -99.90% |
Noticias y actualizaciones recientes
Actualización de narrativa • Aug 04
CRIS: Future Profitability Will Depend On TakeAim CLL Study Progress
Analysts have lifted their price target on Curis to $43 from $17, citing the added valuation for emavusertib in chronic lymphocytic leukemia following the initiation of the TakeAim study and an assumed 10% probability of success on potential peak sales of $500m. Analyst Commentary Recent research on Curis highlights how much of the current valuation hinges on emavusertib and the new TakeAim study in chronic lymphocytic leukemia.Actualización de narrativa • Jul 20
CRIS: Future Profitability Execution Will Rely On TakeAim CLL Trial Progress
Analysts have sharply increased their price target on Curis, raising fair value from $14 to $280. They cite improved leadership, a more focused direct-to-consumer approach, and potential benefits from underappreciated tariff changes as key factors behind the reassessment.Recent updates
Actualización de narrativa • Aug 04
CRIS: Future Profitability Will Depend On TakeAim CLL Study Progress
Analysts have lifted their price target on Curis to $43 from $17, citing the added valuation for emavusertib in chronic lymphocytic leukemia following the initiation of the TakeAim study and an assumed 10% probability of success on potential peak sales of $500m. Analyst Commentary Recent research on Curis highlights how much of the current valuation hinges on emavusertib and the new TakeAim study in chronic lymphocytic leukemia.Actualización de narrativa • Jul 20
CRIS: Future Profitability Execution Will Rely On TakeAim CLL Trial Progress
Analysts have sharply increased their price target on Curis, raising fair value from $14 to $280. They cite improved leadership, a more focused direct-to-consumer approach, and potential benefits from underappreciated tariff changes as key factors behind the reassessment.
Actualización de narrativa • Jul 06
CRIS: TakeAim CLL Progress Will Reshape Perceived Risk Profile
Analysts have sharply increased their price target on Curis to $400 from $20, citing a lower assumed discount rate, higher projected revenue growth, modestly stronger profit margins, and a slightly higher future P/E multiple as the key factors behind the updated view. Analyst Commentary on Curis Recent research updates on Curis signal a clear shift toward a more constructive stance, with bullish analysts pointing to a mix of valuation reset, growth potential, and improving execution as reasons to revisit the stock.Artículo de análisis • Jul 01
Curis (NASDAQ:CRIS) Will Have To Spend Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Actualización de narrativa • Jun 22
CRIS: Future Profitability Execution Will Support Maintained 14 Fair Value
Analysts maintained their $14.00 price target for Curis, citing updated assumptions that combine a lower discount rate with higher projected revenue growth, wider profit margins and a slightly higher future P/E multiple as the main factors behind the refreshed valuation work. Analyst Commentary Recent commentary on Curis centers on how the refreshed $14.00 valuation stacks up against execution risk, profitability assumptions and the path to monetizing the company’s pipeline.
Actualización de narrativa • Jun 05
CRIS: Expanded Share Authorization And Lower P/E Assumptions Will Support Future Upside
Analysts have raised their price target on Curis, citing updated assumptions that now include a slightly lower discount rate, a smaller expected revenue decline, a modestly higher profit margin, and a much lower future P/E multiple to support the change. Analyst Commentary Recent research on Curis points to a mixed backdrop, where some price target adjustments sit alongside a cautious tone on execution and valuation risk.Actualización de narrativa • May 11
CRIS: Expanded Share Authorization Will Support Future Upside Despite Delisting Risks
Analysts raised their price target on Curis by $5, citing updated assumptions for revenue decline, improved profit margin expectations, a slightly lower discount rate, and a reduced future P/E estimate. Analyst Commentary Analyst reactions around Curis highlight a mix of higher price targets and upgraded ratings, but also a thread of caution around how much upside is already reflected in the stock and how execution risk could affect valuation.Actualización de narrativa • Apr 24
CRIS: Expanded Share Authorization And Elevated Future P/E Will Support Upside
Analysts have raised the price target on Curis to $5.00 from $5.00, citing updated assumptions around discount rates, slightly less severe expected revenue contraction, lower profit margins, and a higher future P/E multiple. Analyst Commentary Recent Street research on peer names in the broader consumer space highlights how quickly sentiment can shift when expectations around earnings power, tariff exposure, and valuation multiples come under scrutiny.Actualización de narrativa • Apr 09
CRIS: Expanded Capital Base And Elevated Future P/E Will Support Upside
Analysts have adjusted their price target on Curis to $5.00 from $5.00, citing slightly lower discount rate and revenue decline assumptions, along with a higher future P/E multiple, as key drivers of the updated view. Analyst Commentary Bearish analysts looking at Curis are focusing on how the current valuation lines up with execution risk and the assumptions baked into the updated price target.Actualización de narrativa • Mar 26
CRIS: Expanded Capital Base And Rich Future P/E Will Support Upside
The analyst price target for Curis has been adjusted from $5 to $5.00. Analysts cite a lower discount rate, a shift to expectations of a 15.61% revenue decline, and a significantly higher assumed future P/E multiple as the main factors behind this revision.Actualización de narrativa • Mar 11
CRIS: Maintained US$14 Fair Value Will Depend On Execution Risk
Analysts have maintained their $14.00 price target on Curis while adjusting key inputs, including a slightly lower discount rate, a revised profit margin outlook, and a higher future P/E assumption to reflect updated views on execution risk and valuation support. Analyst Commentary Analysts covering Curis are focusing less on big headline calls and more on how the updated assumptions behind the $14.00 price target line up with execution risk, profitability, and valuation support.Actualización de narrativa • Feb 24
CRIS: Expanded Capital Base And Financing Structure Will Support Long-Term Upside
Narrative update on Curis The analyst price target for Curis has been lifted by $7, with analysts pointing to a slightly lower discount rate, modestly higher revenue growth expectations and a somewhat richer future P/E assumption as key drivers of the change. Analyst Commentary Recent Street research around comparable names highlights how quickly sentiment can swing when execution, growth visibility, or valuation do not line up cleanly.Actualización de narrativa • Feb 10
CRIS: Maintained US$14 Fair Value Will Rely On Clinical Progress
Analysts have kept their price target for Curis steady at US$14.00. The updated view reflects slightly lower discount rate and profit margin assumptions, which are offset by a modestly reduced future P/E multiple.Actualización de narrativa • Jan 25
CRIS: Frontline AML Data And Insider-Backed Financing Will Support Long-Term Upside
Analysts have lifted their price target on Curis to $5.00 from $5.00, citing updated assumptions around higher projected revenue growth and slightly stronger long-term profit margins, partially tempered by a higher discount rate and a lower future P/E multiple. Analyst Commentary Recent Street research on other consumer names highlights several themes that cautious investors are watching closely and that can be relevant when you think about Curis as well.Actualización de narrativa • Jan 10
CRIS: Higher Future P/E And Clinical Progress Will Support Long Term Earnings
Analysts have raised their price target on Curis to $14.00, a change they link to updated assumptions around discount rates, revenue growth, profit margins, and a higher future P/E multiple. Analyst Commentary Analysts are applying a similar playbook across several consumer names, and that context helps explain the recent price target move on Curis.Artículo de análisis • Jan 04
Why Investors Shouldn't Be Surprised By Curis, Inc.'s (NASDAQ:CRIS) 27% Share Price Plunge
Unfortunately for some shareholders, the Curis, Inc. ( NASDAQ:CRIS ) share price has dived 27% in the last thirty days...Actualización de narrativa • Dec 25
CRIS: Frontline AML Data Will Drive Long-Term Upside Despite Heightened Risk
Analysts have cut their price target on Curis from $12.00 to $5.00 as they increase the assumed discount rate, while also lifting revenue growth expectations and lowering future valuation multiples. This reflects a more cautious yet still constructive outlook on the company’s long-term earnings power.Actualización de narrativa • Dec 11
CRIS: Reduced Risk Profile Will Support Long Term Earnings Recovery
Analysts have nudged their price target on Curis modestly higher to $14.00, citing slightly lower perceived risk and a marginally cheaper future earnings multiple. Together, these factors support a cautiously more constructive long term outlook.Actualización de narrativa • Nov 27
CRIS: Cost Efficiencies Will Drive Earnings Recovery Despite Macro Pressures
Curis's analyst price target has been raised modestly, with analysts citing improved profit margin projections and a better cost outlook as reasons for the updated valuation of $14.00 per share. Analyst Commentary Analysts recently updated their perspectives on Curis in light of the company’s latest performance and forward-looking guidance.Artículo de análisis • Nov 20
Curis, Inc. (NASDAQ:CRIS) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
The Curis, Inc. ( NASDAQ:CRIS ) share price has fared very poorly over the last month, falling by a substantial 28...Actualización de narrativa • Nov 13
CRIS: Cost-Saving Initiatives Will Support Stronger Revenue Expansion Into 2026
Curis's analyst price target has been reduced from $16.33 to $14.00. This adjustment reflects analysts' concerns over softer profit margins, even with stronger revenue growth projections and an increased discount rate.Artículo de análisis • Aug 08
Curis, Inc. (NASDAQ:CRIS) Just Reported, And Analysts Assigned A US$16.33 Price Target
NasdaqCM:CRIS 1 Year Share Price vs Fair Value Explore Curis's Fair Values from the Community and select yours Curis...
Nueva narrativa • Apr 14
FDA And EMA Will Accelerate Emavusertib Clinical Trials
Feedback from regulatory bodies can expedite market entry for emavusertib, potentially accelerating revenue and competitive advantage in the CNS lymphoma space.Artículo de análisis • Apr 02
Analysts Just Published A Bright New Outlook For Curis, Inc.'s (NASDAQ:CRIS)
Celebrations may be in order for Curis, Inc. ( NASDAQ:CRIS ) shareholders, with the analysts delivering a significant...Artículo de análisis • Apr 01
Investors Don't See Light At End Of Curis, Inc.'s (NASDAQ:CRIS) Tunnel And Push Stock Down 30%
The Curis, Inc. ( NASDAQ:CRIS ) share price has fared very poorly over the last month, falling by a substantial 30...Artículo de análisis • Dec 29
Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues
Unfortunately for some shareholders, the Curis, Inc. ( NASDAQ:CRIS ) share price has dived 26% in the last thirty days...Artículo de análisis • Nov 14
Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues
Curis, Inc. ( NASDAQ:CRIS ) shareholders won't be pleased to see that the share price has had a very rough month...Artículo de análisis • Aug 07
Growth Investors: Industry Analysts Just Upgraded Their Curis, Inc. (NASDAQ:CRIS) Revenue Forecasts By 15%
Curis, Inc. ( NASDAQ:CRIS ) shareholders will have a reason to smile today, with the analysts making substantial...Artículo de análisis • Aug 05
Improved Revenues Required Before Curis, Inc. (NASDAQ:CRIS) Shares Find Their Feet
With a price-to-sales (or "P/S") ratio of 2.9x Curis, Inc. ( NASDAQ:CRIS ) may be sending very bullish signals at the...Artículo de análisis • Apr 03
Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Curis, Inc. ( NASDAQ:CRIS ) shareholders are no doubt pleased to see that the share price has bounced 27% in the last...Rentabilidad de los accionistas
| CRIS | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -55.2% | 0.5% | 0.6% |
| 1Y | -95.1% | 35.4% | 19.9% |
Rentabilidad vs. Industria: Los resultados de CRIS fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 37.4% el año pasado.
Rentabilidad vs. Mercado: CRIS obtuvo unos resultados inferiores a los del mercado US, que fueron del 20% el año pasado.
Volatilidad de los precios
| CRIS volatility | |
|---|---|
| CRIS Average Weekly Movement | 29.5% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: El precio de las acciones de CRIS ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de CRIS ha aumentado de 18% a 29% en el último año.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2000 | 22 | Jim Dentzer | www.curis.com |
Curis, Inc, empresa biotecnológica, se dedica al descubrimiento y desarrollo de fármacos candidatos para el tratamiento de cánceres humanos en Estados Unidos. Entre sus candidatos a fármacos en fase clínica figura Emavusertib, un inhibidor oral de la cinasa IRAK4 de molécula pequeña, que se encuentra en un ensayo abierto de fase 1/2 de un solo brazo en pacientes con linfoma primario del sistema nervioso central en recaída o refractario. La cartera de productos de la empresa también incluye Fimepinostat, un inhibidor dual oral de las enzimas HDAC y PI3K para el tratamiento de pacientes con linfoma difuso de células B grandes en recaída o resistente al tratamiento; CA-170, un antagonista oral de molécula pequeña designado como CA-170 que se dirige selectivamente a PD-L1 y VISTA; y CA-327, una molécula oral pequeña, TIM3/PD-L1, que es una molécula antagonista de PD-L1 y TIM3.
Resumen de fundamentos de Curis, Inc.
| Estadísticas fundamentales de CRIS | |
|---|---|
| Capitalización bursátil | US$3.64m |
| Beneficios(TTM) | -US$21.16m |
| Ingresos (TTM) | US$7.06m |
0.5x
Ratio precio-ventas (PS)-0.2x
Ratio precio-beneficio (PE)¿Está CRIS sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de CRIS | |
|---|---|
| Ingresos | US$7.06m |
| Coste de los ingresos | US$26.31m |
| Beneficio bruto | -US$19.25m |
| Otros gastos | US$1.92m |
| Beneficios | -US$21.16m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -10.86 |
| Margen bruto | -272.49% |
| Margen de beneficio neto | -299.66% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado CRIS a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/14 03:33 |
| Precio de las acciones al final del día | 2026/08/14 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Curis, Inc. está cubierta por 17 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Brian Skorney | Baird |
| James Birchenough | BMO Capital Markets Equity Research |
| Justin Walsh | B. Riley Securities, Inc. |